The influence of matriptase-2 on prostate cancer in vitro: A possible role for β-catenin

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1491-1497

  Webb, Siobhan L ^a   Sanders, Andrew J ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

catenin; Matriptase 2; Prostate cancer; Type II transmembrane serine protease

Indexed keywords

BETA CATENIN; MESSENGER RNA;

ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MEMBRANE; CELL MOTILITY; CONTROLLED STUDY; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MATRIPTASE 2 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RIBOZYME VECTOR; TRANSGENE; TUMOR GENE;

BASE SEQUENCE; BETA CATENIN; CELL ADHESION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PROSTATE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANSGENES;

EID: 84866459890     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1945     Document Type: Article

References (26)

1. Lang JC and Schuller DE: Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 84: 237-243, 2001.
2. Lee JW, Yong Song S, Choi JJ, et al: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36: 626-633, 2005.
3. Magee JA, Araki T, Patil S, et al: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696, 2001.
4. Netzel-Arnett S, Hooper JD, Szabo R, et al: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22: 237-258, 2003.
5. Wallrapp C, Hahnel S, Muller-Pillasch F, et al: A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 60: 2602-2606, 2000.
6. Velasco G, Cal S, Quesada V, Sanchez LM and Lopez-Otin C: Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 277: 37637-37646, 2002.
7. Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H and Quigley JP: Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 373: 689-702, 2003.
8. Szabo R and Bugge TH: Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 40: 1297-1316, 2008.
9. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME and Dickson RB: Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53: 1409-1415, 1993.
10. Tsai WC, Chu CH, Yu CP, et al: Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 24: 89-99, 2008.
11. Uhland K: Matriptase and its putative role in cancer. Cell Mol Life Sci 63: 2968-2978, 2006.
12. Parr C, Sanders AJ, Davies G, et al: Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 13: 3568-3576, 2007.
13. Sanders AJ, Parr C, Martin TA, Lane J, Mason MD and Jiang WG: Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol 216: 780-789, 2008.
14. Hart M, Concordet JP, Lassot I, et al: The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9: 207-210, 1999.
15. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
16. Brabletz T, Jung A, Dag S, Hlubek F and Kirchner T: beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155: 1033-1038, 1999.
17. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891, 1999.
18. Zhang X, Gaspard JP and Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050-6054, 2001.
19. Boon EM, van der Neut R, van de Wetering M, Clevers H and Pals ST: Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62: 5126-5128, 2002.
20. Chesire DR, Ewing CM, Sauvageot J, Bova GS and Isaacs WB: Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45: 323-334, 2000.
21. Gerstein AV, Almeida TA, Zhao G, et al: APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34: 9-16, 2002.
22. Voeller HJ, Truica CI and Gelmann EP: Beta-catenin mutations in human prostate cancer. Cancer Res 58: 2520-2523, 1998.
23. Chesire DR, Ewing CM, Gage WR and Isaacs WB: In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679-2694, 2002.
24. de la Taille A, Rubin MA, Chen MW, et al: Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9: 1801-1807, 2003.
25. Gounari F, Signoretti S, Bronson R, et al: Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21: 4099-4107, 2002.
26. Bierie B, Nozawa M, Renou JP, et al: Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22: 3875-3887, 2003.